Targeting TIGIT to improve outcomes in advanced HCC

By afschroeder • February 5, 2026

Bejjani AC, Roayaie S, Finn RS. Targeting TIGIT to improve outcomes in advanced HCC. JHEP Rep. 2025 Oct 9;7(11):101552. doi: 10.1016/j.jhepr.2025.101552. PMID: 41635625; PMCID: PMC12861928.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]